Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome

Fig. 4

Kaplan-Meier curve for all cause death (a) CV death (b) non-fatal stroke (c) and composite MACCE (d) of the ACEI/ARB(-) group (red line) versus the ACEI/ARB(+) group (green line). a There was no significant difference in the cumulative rate of all cause death between the 2 groups. b There was no significant difference in the cumulative rate of CV death between the 2 groups. c The cumulative rate of non-fatal stroke in the ACEI/ARB(-) group was significantly higher than that in the ACEI/ARB(+) group(p < 0.05). d The cumulative rate of composite MACCE in the ACEI/ARB(-) group was significantly higher than that in the ACEI/ARB(+) group (p < 0.05). ACEI/ARB angiotensin-converting enzyme inhibitor/Angiotensin receptor blocker, CV Cardiovascular, MACCE major adverse cardiac and cerebral event

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us